Go to contentGo to menuGo to searchGo to the news list

Micro et Nanomédecines Translationnelles

Main navigation

    Search

    Breadcrumb

    FP7_TRANS-INT(2012-17)

    FP7_TRANS-INT(2012-17)

    • Share this page on social networks
    • E-mail this page

      Send by mail


      Separated by coma
    • Print this page

    Coordinator : Pr. Maria José Alonso

    Nanovecteur

    This is a large-scale collaborative research project within the 7th European Framework Program  for Research and Technological Development. The TRANS-INT project will run from May 1st, 2012 to April 30th, 2017.

     

    In TRANS-INT a clear concept and shared ambition provide the cohesive force. The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering and pharmaceutical technology criteria.

     

    The consortium is composed of 16 partners from industry and academia with complementary leading expertise in chemistry, chemical engineering, pharmaceutical technology, molecular physiology, biopharmaceutics, toxicology and drug development.

     

    TRANSINT combines expertise in pharmaceutical nanotechnology, biochemistry, immunology, toxicology, biology and physiology with the aim to develop a novel nanodrug candidate able to effectively fight diabetes. TRANSINT researchers will make use of nanotechnology to find new oral ways for drug delivery that can become an alternative to insulin injection, thus improving the quality of life of patients with diabetes.

     

    more details...

    Project leader


    Associated meeting

    Crossing Biological Barriers – Advances in Nanocarrier Design for Targeted Drug Delivery

    9 – 11 November 2015
    The Westin Bellevue Dresden

    more details